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Objectives. This study sought to determine the significance of
abnormal thallium-201 (Tl-201) lung uptake on stress imaging in
the absence of perfusion abnormalities.
Background. Abnormal Tl-201 lung uptake, represented by an
increased lung/heart ratio (LHR), on stress imaging is a marker
of stress-induced left ventricular dysfunction and poor prognosis
in patients with coronary artery disease.
Methods. We evaluated 1,271 patients from the Thrombolysis in
Myocardial Infarction (TIMI)-IIIB trial (86% of TIMI-IIIB co-
hort) with unstable angina or non-Q wave myocardial infarction,
who underwent predischarge exercise (92%) or dipyridamole
stress (8%) Tl-201 imaging. An increased LHR (>20.50) was
related to perfusion abnormalities and adverse cardiac events at 1
year.
Results. Of 1,271 patients, there were 762 (60%) with and 509
(40%) without perfusion abnormalities. An increased LHR was
seen in 227 patients (18%) (173 [23%] with, 54 [11%] without
perfusion abnormalities). Patients with an increased LHR had a
lower left ventricular ejection fraction, higher body weight, lower
exercise capacity and a higher prevalence of angina on exercise
than patients with a normal LHR. In the two groups with
increased LHR, there was no difference in age, hypertension,
previous myocardial infarction, total exercise time, frequency of
angina and ST segment depression on exercise. However, the
group with an increased LHR and normal myocardial perfusion
had a preponderance of women (65% vs. 30%, p < 0.001). At
1-year follow-up, patients with an increased LHR had a higher
cardiac event rate than those with a normal LHR (18% vs. 10%,
respectively, p 5 0.001) despite a higher revascularization rate
(28% vs. 15%, p < 0.001). An increased LHR was associated with
increased adverse cardiac events, irrespective of the presence or
absence of perfusion abnormalities.
Conclusions. An increased LHR continues to be associated with
higher adverse cardiac events in the current era of aggressive
interventional management of coronary artery disease. An in-
creased LHR in the absence of myocardial perfusion abnormality
is seen mostly in women and overweight patients. However,
despite the apparent absence of perfusion abnormalities, an
increased LHR in this group is also associated with a higher rate
of adverse cardiac events.
(J Am Coll Cardiol 1997;30:421–9)
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Exercise stress myocardial perfusion imaging provides impor-
tant information about the extent of myocardial ischemia and
scar in patients with coronary artery disease (1–3). This
technique is used routinely for the clinical evaluation and risk
stratification of patients with coronary artery disease. With
thallium-201 (Tl-201) imaging, an increased lung/heart ratio
(LHR) provides additional relevant diagnostic and prognostic
information (4–8). Several studies have shown abnormal lung
Tl-201 uptake also to be associated with greater segmental
myocardial perfusion abnormality, increased severity and ex-
tent of coronary artery disease and impaired left ventricular
function (5,8–10). Follow-up studies have shown (11–13) ab-
normal lung Tl-201 uptake to be the most important predictor
of subsequent adverse cardiac events. Abnormal lung Tl-201
uptake during pharmacologic stress imaging has similar clinical
significance to that noted during exercise (14,15).
Most studies evaluating increased LHR were carried out
before the widespread use of thrombolytic agents or aggressive
interventional treatment of patients with coronary artery dis-
ease. Consequently, the clinical and prognostic significance of
this finding in the context of current management of patients
with coronary artery disease is not well defined. Moreover,
abnormal lung Tl-201 uptake is occasionally seen in patients
without any myocardial perfusion abnormality. The signifi-
cance of abnormal lung Tl-201 uptake in this circumstance is
also not known. To address these issues, we analyzed the data
base of the Thrombolysis in Myocardial Infarction (TIMI)-
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IIIB study, which included a large cohort of well characterized
patients presenting with acute coronary syndromes who also
underwent stress Tl-201 imaging.
Methods
TIMI-IIIB was a prospective, multicenter clinical trial in-
volving 1,473 patients designed to test the efficacy of throm-
bolytic therapy versus placebo, and early invasive strategy
versus early conservative strategy for the management of
patients admitted with unstable angina or non-Q wave myo-
cardial infarction (16,17). As part of the study protocol,
patients underwent predischarge myocardial perfusion imag-
ing. Patients were enrolled in 25 centers in the United States
and 6 in Canada, and the study was supported by six core
laboratories and two central units (17). The details of the study
design, participants, study cohort and overall study results have
been described previously (17).
Patients. Patients presenting with chest pain judged to be
ischemic in origin but without any evidence of Q wave myo-
cardial infarction were enrolled. The inclusion and exclusion
criteria have been described in detail (17). In brief, patients
with chest pain lasting $5 min but #6 h in the preceding 24 h
with objective evidence of ischemic heart disease were entered
into the study. The objective evidence of myocardial ischemia
included at least one of the following: 1) transient ST segment
elevation or new ST segment depression or T wave inversion in
at least two contiguous leads; 2) previous history of myocardial
infarction; 3) $70% lumen narrowing of at least one or more
coronary arteries on previous coronary angiography; 4) evi-
dence of ischemia on previous stress Tl-201 imaging. Patients
with electrocardiographic (ECG) findings consistent with acute
Q wave myocardial infarction were not entered into the study.
Additional exclusion criteria included contraindication to
thrombolytic therapy or heparin, myocardial infarction in the
preceding 21 days, coronary angiography within 30 days,
percutaneous transluminal coronary angioplasty (PTCA)
within 6 months, coronary artery bypass graft surgery (CABG)
in the past, pulmonary edema or hypotension at presentation,
left bundle branch block, a coexisting serious ailment, women
of child-bearing potential and concurrent treatment with oral
anticoagulant agents.
All patients were to be treated with heparin, aspirin and
vigorous antianginal therapy. The patients were randomly
assigned in double-blind fashion to treatment with tissue-type
plasminogen activator (t-PA) versus placebo and to an early
invasive strategy (coronary angiography followed by revascu-
larization of suitable coronary anatomy within 18 to 48 h of
admission) versus an early conservative strategy (coronary
angiography and revascularization only in the event of failure
of initial therapy) using a 2 3 2 factorial design (Table 1).
Irrespective of the randomization category, all patients were
assigned to undergo predischarge stress Tl-201 imaging.
Stress Tl-201 imaging. The protocol mandated stress Tl-
201 imaging before discharge in all patients. Those capable of
exercising underwent treadmill exercise using a modified Bruce
protocol. Patients unable to exercise underwent pharmacologic
stress with intravenous dipyridamole. End points for treadmill
exercise were severe chest pain, severe shortness of breath,
fatigue, appearance of serious arrhythmias, hypotension
($10-mm systolic blood pressure fall) or completion of three
stages of exercise. Tl-201 (2.0 to 2.5 mCi) was injected at peak
exercise, and the exercise was continued for another 1.5 to
2.0 min. Planar myocardial perfusion imaging was started
within 5 to 10 min of injection and was repeated 2.5 to 4 h later.
Three standard planar views (anterior, left anterior oblique,
left lateral) were acquired. Patients undergoing pharmacologic
stress received 0.56 mg/kg body weight of dipyridamole intra-
venously over 4 min, with continuous monitoring of blood
pressure and ECG, and 2.0 to 2.5 mCi of Tl-201 was injected
4 min after completion of the dipyridamole infusion. Planar
imaging was started within 5 to 10 min of the injection of
Tl-201. Each view was acquired for 8 min. All images were
stored on a floppy disk and were transferred to the Yale
University Radionuclide Core Laboratory for uniform image
processing, quantification and blinded interpretation by one of
the two readers (B.L.Z., F.W.).
Tl-201 image interpretation. Images were interpreted us-
ing quantitative previously described methods (18). In brief,
paired unprocessed stress–redistribution images were dis-
played for initial visual interpretation. Circumferential count
Abbreviations and Acronyms
CABG 5 coronary artery bypass graft surgery
ECG 5 electrocardiogram, electrocardiographic
LHR 5 lung/heart ratio
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
Tl-201 5 thallium-201
t-PA 5 tissue-type plasminogen activator
Table 1. Patient Population
Total Pts
Entered
Into Study
(n 5 1,473)
Pts With
Predischarge
Tl-201
(n 5 1,271)
Pts Without
Predischarge
Tl-201
(n 5 202)
Mean age (yr) 59 59 60
Women (%) 34 33 38
Randomization
t-PA
Early invasive 367 302 65
Conservative 362 332 30
Placebo
Early invasive 373 306 67
Conservative 371 331 40
Data presented are number of patients, unless otherwise indicated. Pts 5
patients; Tl-201 5 thallium-201; t-PA 5 tissue-type plasminogen activator.
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distribution profiles were generated after background subtrac-
tion and smoothing. These were compared to the normal
database profiles obtained from a cohort of normal subjects
with a low likelihood of coronary artery disease. Segments
,2 SD of the averaged normal profile were considered abnor-
mal. Left ventricular myocardium in each view was divided into
five segments, and each segment was scored as normal, scar,
ischemia or mixed (scar and ischemia).
Lung Tl-201 activity was assessed from the quantitative
LHR obtained from the unprocessed left anterior oblique
images (the first view acquired after tracer injection) by
obtaining a ratio of average counts/pixel in the left ventricular
myocardium and the left lung. This was done automatically by
placing a 3 3 3-pixel region of interest over the left ventricular
myocardium with highest counts and a similar-sized region of
interest over the left upper lung field. A ratio $0.5 was
considered indicative of abnormal lung Tl-201 uptake. High
risk studies were predefined as those with 1) multiple areas of
reversible perfusion abnormalities in more than one vascular
territory; 2) a single large area of reversible perfusion abnor-
mality; or 3) reversible perfusion abnormality with an in-
creased LHR. According to the TIMI-IIIB protocol, the
presence of high risk Tl-201 images was an indication for
coronary angiography and consideration for revascularization
if appropriate. An increased LHR in the absence of a revers-
ible perfusion abnormality was predefined not to be an indi-
cation for cardiac catheterization.
Cardiac catheterization. Patients randomized to the early
invasive strategy underwent cardiac catheterization, left ven-
tricular angiography and coronary arteriography 18 to 48 h
after randomization. Coronary angiography was performed in
multiple projections using standard techniques, and left ven-
triculography was performed in the right anterior oblique view.
Left ventricular ejection fraction was calculated from the left
ventriculogram. Angiograms were reviewed immediately at the
local center to ascertain the presence of a culprit lesion and
were followed by revascularization, if possible. PTCA was the
preferred modality for revascularization and was performed
after the initial angiography or as soon as possible thereafter,
if the culprit lesion was amenable to angioplasty. In patients
with multivessel coronary artery disease, PTCA of major
vessels other than the culprit artery was also performed in an
attempt to maximally reduce ischemia. CABG was performed
in patients with $50% narrowing of the left main coronary
artery or with three-vessel disease and a depressed left ven-
tricular ejection fraction (#40%) or in those whose coronary
Table 2. Clinical Characteristics of Study Patients According to
Presence or Absence of Increased Lung Thallium-201 Uptake
Increased Lung
Tl-201 Uptake
(n 5 227 [18%])
Normal Lung
Tl-201 Uptake
(n 5 1,044 [82%])
p
Value
Mean age (yr) 58 59 0.77
Women (%) 38 32 0.06
Hypertension (%) 47 41 0.14
Height (cm) 168 168 0.5
Weight (kg) 85 78 , 0.001
Unstable angina (%) 66 69 0.44
Prior MI (%) 45 39 0.11
.60% occlusion on cor
angio (%)*
0 vessel 15 21
1 vessel 43 39
$2 vessels 43 40 0.4
LVEF (%)* 54 60 , 0.0005
Abnormal perfusion (%) 76 56 , 0.0001
LHR 0.7 0.4 , 0.0005
Early invasive strategy (%) 36 50 , 0.001
t-PA treatment (%) 55 49 0.12
Total ex time (s)† 434 495 , 0.0001
Peak HR (beats/min) 107 119 , 0.0001
Peak SBP (mm Hg) 164 160 , 0.52
Angina on ex (%) 22 15 0.006
ST dep $1 mm on ex (%) 27 22 0.074
*Available only in patients randomized to early invasive strategy: 82 patients
with increased lung thallium-201 (Tl-201) uptake, 516 with normal lung Tl-201
uptake. †Available for 209 patients with increased lung Tl-201 uptake, 957 with
normal Tl-201 uptake. Data presented are percent of patients, unless otherwise
indicated. cor angio 5 coronary angiogram; ex 5 exercise; HR 5 heart rate;
LHR 5 lung/heart ratio; LVEF 5 left ventricular ejection fraction; MI 5
myocardial infarction; SBP 5 systolic blood pressure; ST dep 5 ST segment
depression; t-PA 5 tissue-type plasminogen activator.
Table 3. Characteristics of Groups I and III (groups with increased
lung thallium-201 uptake)
Group I
(perfusion
abnormalities)
(n 5 173)
Group III
(no perfusion
abnormalities)
(n 5 54)
p
Value
Mean age (yr) 59 58 0.65
Women (%) 30 65 , 0.001
Hypertension (%) 43 57 0.07
Height (cm) 169 166 0.04
Weight (kg) 85 84 0.68
Unstable angina (%) 62 80 0.02
Prior MI (%) 47 35 0.12
.60% occlusion on cor
angio (%)*
0 vessel 7 32
1 vessel 46 36
$2 vessels 47 32 0.01
LVEF (%)* 52 60 0.016
LHR 0.68 0.73 0.76
Early invasive strategy (%) 33 46 0.07
t-PA treatment (%) 53 59 0.43
Total ex time (s)† 444 407 0.23
Peak HR (beats/min) 107 104 0.38
Peak SBP (mm Hg) 163 167 0.87
Angina on ex (%) 25 15 0.1
ST dep $1 mm on ex (%) 30 19 0.13
*Available only in patients randomized to early invasive strategy: 57 patients
in thallium-201 (Tl-201) defect group, 25 in no Tl-201 defect group. †Available
in 161 Group I patients and 48 Group III patients. Data presented are percent
of patients, unless otherwise indicated. Abbreviations as in Table 2.
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anatomy was not suitable for PTCA. Patients randomized to
the early conservative strategy underwent cardiac catheteriza-
tion only after failure of initial therapy, as indicated by the
recurrence of angina, or on the basis of the finding of high risk
predischarge stress Tl-201 imaging or $20 min of ischemic ST
segment depression on 24-h Holter monitoring or if unstable
angina recurred after hospital discharge, as previously defined
(17). Coronary angiographic and ejection fraction data were
available only for patients who were randomized to the early
invasive strategy group.
Follow-up. The patient, family or physician were contacted
at 1 year (range 365 to 550 days after randomization) and
questioned concerning the occurrence of adverse cardiac
events defined as death, nonfatal myocardial infarction or
spontaneous ischemia requiring hospital admission.
Statistical analysis. The Student unpaired t test was used
for continuous dependent variables and chi-square analysis
was used for categoric dependent variables. Kaplan-Meier
curves of adverse events over a follow-up period of 1 year were
plotted for different groups of patients and, if appropriate,
were compared using the log-rank statistic. As in previous
TIMI publications, because of the large number of analyses
performed, p 5 0.01 was considered evidence of an associa-
tion; p 5 0.001 was considered strong evidence of an associa-
tion; and p # 0.05 and .0.01 were considered to indicate a
trend (16,17,19–21).
Results
Of a total of 1,473 patients enrolled in the study, 1,271
(86%) underwent stress Tl-201 imaging (92% treadmill exer-
cise, 8% dipyridamole stress). The remaining 202 patients did
not undergo perfusion imaging because of death before dis-
charge (26 patients), physician or patient refusal or equipment
malfunction (176 patients) (Table 1). Of the 1,271 patients who
underwent imaging, 762 (60%) had perfusion abnormalities
(reversible defects in 530 [42%], fixed defects in 232 [18%]);
509 patients (40%) had no perfusion abnormalities. Abnormal
lung Tl-201 uptake was observed in 227 (18%) patients. The
prevalence of increased LHR in patients with and without
perfusion abnormalities was 23% (n 5 173) and 11% (n 5 54),
respectively (p , 0.0001). The patients were classified into four
groups according to the presence or absence of perfusion
abnormalities and the presence or absence of an increased
LHR, as follows: Group I 5 presence of perfusion abnormality
with an increased LHR (n 5 173 [14%]); Group II 5 presence
of perfusion abnormality with a normal LHR (n 5 589 [46%]);
Group III 5 no perfusion abnormality with an increased LHR
(n 5 54 [4%]); Group IV 5 no perfusion abnormality with a
normal LHR (n 5 455 [36%]).
When all patients with an increased LHR were compared
with patients with a normal LHR, no differences in age,
gender, prevalence of hypertension and angiographic extent of
coronary artery disease were seen (Table 2). Patients with an
increased LHR had a higher body weight (85 vs. 78 kg, p ,
0.001) than the patients with a normal LHR. A greater
proportion of patients with an increased LHR had a perfusion
abnormality (173 of 227 vs. 589 of 1,044, p , 0.0001) compared
with patients with a normal LHR. A smaller proportion of
Table 4. Clinical Characteristics of Groups IV and III (groups with
no perfusion abnormalities)
Group IV
(normal LHR)
(n 5 455)
Group III
(inc LHR)
(n 5 54)
p
Value
Mean age (yr) 58 58 0.87
Women (%) 39 65 , 0.0005
Hypertension (%) 39 57 0.01
Height (cm) 167 166 0.59
Weight (kg) 77 84 , 0.001
Unstable angina (%) 75 80 0.46
Prior MI (%) 28 35 0.28
.60% occlusion on cor
angio (%)*
0 vessel 29 32
1 vessel 42 36
$2 vessels 29 32 0.85
LVEF (%)* 63 60 0.09
LHR 0.36 0.73 , 0.001
Early invasive strategy (%) 58 46 0.1
t-PA treatment (%) 48 59 0.11
Total ex time (s)† 516 407 , 0.0001
Peak HR (beats/min) 119 104 , 0.0001
Peak SBP (mm Hg) 160 167 ,0.41
Angina on ex (%) 11 15 0.46
ST dep $1 mm on ex (%) 14 19 0.35
*Available only in patients randomized to early invasive strategy: 263
patients with normal lung/heart ratio (LHR), normal perfusion group; 25 with
increased (inc) lung/heart ratio, no thallium-201 defect group. †Available in 421
Group IV patients and 48 Group III patients. Data presented are percent of
patients, unless otherwise indicated. Abbreviations as in Table 2.
Table 5. Frequency of Coronary Angioplasty or Bypass Surgery at
42 Days After Thallium-201 Imaging
Increased
LHR
Normal
LHR
p
Value
All pts n 5 227 n 5 1,044
PTCA 28 (12%) 94 (9%) 0.12
CABG 37 (16%) 63 (6%) , 0.001
PTCA/CABG 64 (28%) 152 (15%) , 0.001
Perf abn n 5 173 n 5 589
PTCA 22 (13%) 69 (12%) 0.73
CABG 34 (20%) 53 (9%) , 0.001
PTCA/CABG 55 (32%) 118 (20%) 0.002
No perf abn n 5 54 n 5 455
PTCA 6 (11%) 25 (6%) 0.10
CABG 3 (6%) 10 (2%) 0.13
PTCA/CABG 9 (17%) 34 (8%) 0.02
Data presented are number (%) of patients (pts). CABG 5 coronary artery
bypass graft surgery; LHR 5 lung/heart ratio; Perf abn 5 perfusion abnormal-
ities; PTCA 5 percutaneous transluminal coronary angioplasty.
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patients with an increased LHR were randomized to early
invasive strategy (82 of 227 vs. 526 of 1,044, p , 0.001), but
there was no difference in treatment with t-PA (124 of 227 vs.
510 of 1,044, p 5 0.12). Patients with an increased LHR had a
lower total treadmill exercise time (434 6 184 vs. 495 6 191 s,
p , 0.0001), lower peak heart rate (107 6 20 vs. 119 6 22
beats/min, p , 0.0001), lower peak blood pressure (148 6 27
vs. 158 6 28 mm Hg, p , 0.0001) and a higher frequency of
angina (22% vs. 15%, p 5 0.006) but no difference in the
frequency of abnormal ST segment depression on the exercise
ECG (27% vs. 22%, p 5 NS) than patients with a normal LHR
(Table 2).
When the two groups with increased LHR (Groups I and
III) were compared, there was no difference in age, prevalence
of hypertension or previous myocardial infarction (Table 3).
However, Group III had more women (65% vs. 30%, p ,
0.001) and a lower prevalence of multivessel coronary artery
disease in those undergoing angiographic evaluation (32% vs.
47%, p 5 0.01) than Group I. The exercise time (407 6 178 vs.
444 6 186 s, p 5 0.23), frequency of angina (15% vs. 25%, p 5
0.1) and $1-mm ST segment depression (19% vs. 30%, p 5
0.13) were not different between Groups III and I. There was
no difference in peak heart rate and peak systolic blood
pressure. There was no difference in randomization to treat-
ment categories (Table 3).
When the two groups with normal myocardial perfusion
(Groups III and IV) were compared, there were no differences
in age, angiographic extent of coronary artery disease or left
ventricular ejection fraction (Table 4). However, Group III
had more women (65% vs. 39%, p , 0.001) and a higher mean
body weight (85 vs. 76 kg, p 5 0.001) than Group IV. Group IV
patients had a higher exercise time (516 6 196 vs. 407 6 178 s,
p , 0.0001), greater peak heart rate (119 6 23 vs. 104 6 16
beats/min, p , 0.0001) and no difference in peak systolic
pressure (160 6 28 vs. 167 6 28 mm Hg, p , 0.41) than Group
III patients. There was no difference in frequency of angina or
ST segment depression (Table 4) and no difference in random-
ization to the treatment category.
Revascularization procedures. The frequency of revascu-
larization procedures (PTCA or CABG) at 42 days of
follow-up is shown in Table 5 for different groups of patients.
The decision to perform these procedures was based on the
presence of high risk predischarge Tl-201 images (as previously
defined), recurrence of angina either during the hospital stay
or after discharge or the occurrence of spontaneous ischemia
($20 min of ischemic ST segment deviation on 24-h Holter
Figure 1. Adverse cardiac events in
patients with increased and normal
lung Tl-201 uptake over a follow-up
period of 1 year. Top, All cardiac
events. Bottom, Myocardial infarc-
tion and death only.
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monitor), as previously defined (17). Of the entire patient
group, 216 (17%) underwent a revascularization procedure
(PTCA or CABG). A total of 122 patients had PTCA, and 100
had CABG (6 underwent CABG after they had undergone
PTCA). Twenty-eight percent of patients with an increased
LHR underwent revascularization compared with 15% pa-
tients with a normal LHR (p , 0.001). In the patients with
perfusion abnormalities, 32% with an increased LHR (Group
I) underwent revascularization compared with 20% with a
normal LHR (Group II) (p 5 0.002), whereas in patients
without perfusion abnormalities, 17% with an increased LHR
(Group III) underwent revascularization compared with 8%
with a normal LHR (Group IV) (p 5 0.02). The higher
incidence of revascularization procedures in the presence of an
increased LHR clearly reflects the fact that an increased LHR
in the presence of reversible perfusion abnormalities, accord-
ing to the predefined protocol, was an indication for revascu-
larization, when possible.
Follow-up. Figure 1 shows cardiac event rates over a
follow-up period of 1 year in patients with increased versus
normal lung Tl-201 uptake for the total patient cohort. There
was strong evidence that patients with increased lung Tl-201
uptake had higher frequency of all adverse events (p 5 0.001),
but there was no statistical difference in the incidence of the
“hard events” of death or myocardial infarction. Figure 2
shows the follow-up results in patients with and without an
increased LHR in the presence of perfusion abnormalities
(Group I vs. Group II). Patients with an increased LHR had a
trend toward higher cardiac events (p 5 0.025), although this
did not achieve the predetermined level of statistical signifi-
cance. Figure 3 shows the follow-up results in patients with and
without an increased LHR with no perfusion abnormalities
(Group III vs. Group IV). There is no statistical difference in
the incidence of all cardiac events, but there is a trend toward
higher incidence of death and myocardial infarction in patients
with increased lung Tl-201 uptake with no perfusion abnor-
malities (p 5 0.016). Therefore, despite higher rates of revas-
cularization procedures, patients with an increased LHR had a
higher rate of adverse cardiac events over the subsequent 1
year.
Discussion
Comparison with previous studies. This study shows that
increased LHR on predischarge stress Tl-201 imaging in
patients with unstable angina or non-Q wave myocardial
Figure 2. Adverse cardiac events
in patients with perfusion abnor-
malities based on the presence
(solid lines) or absence (dotted
lines) of increased lung Tl-201
uptake over a follow-up period of
1 year. Top, All cardiac events.
Bottom, Myocardial infarction
and death.
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infarction in the current interventional era continues to be
predictive of higher adverse cardiac event rates over the
ensuing year. An increased LHR was associated with lower
treadmill exercise time, lower peak heart rate, lower peak
systolic blood pressure and a higher frequency of angina on
exercise. These results are in agreement with studies per-
formed before the widespread use of interventional treatment,
when an increased LHR was found to be an adverse prognostic
sign in patients with coronary artery disease and was associated
with greater extent of coronary artery disease and greater
impairment of left ventricular ejection fraction. In the present
study, a higher incidence of adverse cardiac events was ob-
served in patients with an increased LHR, despite the fact that
an increased LHR in the presence of reversible perfusion
abnormalities (i.e., inducible ischemia) was one of the protocol
criteria for cardiac catheterization and revascularization.
There was a higher rate of revascularization procedures in
patients with an increased LHR at 42 days (28% vs. 15%, p ,
0.001) than in patients with normal lung Tl-201 uptake.
Despite a nearly twofold higher rate of intervention, patients
with increased lung Tl-201 uptake had a higher adverse cardiac
event rate at 1 year. One might expect a lower rate of adverse
cardiac events with greater use of revascularization proce-
dures. These differences were seen when all cardiac events
(death, nonfatal myocardial infarction and spontaneous isch-
emia) were taken into consideration. It should be noted that
there was a relatively small number of deaths and myocardial
infarctions at 1 year (,8%) in this patient cohort, consistent
with the current low 1-year rates of mortality and infarction in
patients with acute coronary artery disease (22). There was a
strong association (p 5 0.001) between an increased LHR and
adverse cardiac events in the overall patient cohort. However,
the association could not be further explored in individual
patient subgroups because of the relatively lower number of
adverse cardiac events.
Effect of treatment. When the effect of treatment assign-
ment on increased LHR was evaluated, there was no difference
in treatment with t-PA, but a significantly lower proportion of
patients with an increased LHR were in the early invasive
treatment group (36% vs. 50%), which suggests a possible
greater efficacy of early invasive strategy in these patients than
more conservative strategies.
Increased LHR without perfusion abnormalities. In-
creased LHR without apparent perfusion abnormalities was
seen in a relatively small proportion of patients (4% of the
entire patient cohort). Despite an apparent absence of perfu-
sion abnormalities, a trend toward a higher adverse cardiac
event rate persisted in this group. An increased LHR with no
Figure 3. Adverse cardiac events in
patients with no perfusion abnor-
malities based on the presence (sol-
id lines) or absence (dotted lines)
of increased lung Tl-201 uptake
over a follow-up period of 1 year.
Top, All cardiac events. Bottom,
Myocardial infarction and death.
427JACC Vol. 30, No. 2 JAIN ET AL.
August 1997:421–9 INCREASED LUNG THALLIUM UPTAKE
perfusion abnormalities was seen more often in women and in
patients with a higher body weight. It is possible that an
increased LHR in this group may in part be an artifact of
nonuniform soft tissue attenuation rather than a result of
exercise-induced left ventricular dysfunction. Because breast
and other soft tissue may overlap the cardiac region of interest
more than the lung fields, more of the radioactivity emanating
from the heart would be attenuated than that from the lung
fields, thereby resulting in an artifactually higher LHR. Nev-
ertheless, despite an apparent lack of perfusion abnormalities,
these patients demonstrated a trend toward a higher adverse
cardiac event rate on follow-up than those with normal lung
Tl-201 uptake with no perfusion abnormalities. Artifact of soft
tissue attenuation alone may not be entirely responsible for
this phenomenon. Soft tissue attenuation may also result in
difficulty in identifying perfusion abnormalities and in differ-
entiating true perfusion abnormalities from the attenuation
artifacts. Lower workload on exercise as indicated by lower
total exercise time and peak heart rate in this group may also
have contributed to an apparent lack of perfusion abnormali-
ties in this group. This in turn may have resulted in lower rates
of cardiac catheterization and revascularization in these pa-
tients: 17% of patients with abnormal lung Tl-201 uptake and
normal myocardial perfusion (Group III) underwent revascu-
larization compared with 32% of patients with increased lung
Tl-201 uptake and perfusion abnormalities. It is also possible
that a higher body weight in this cohort may be an independent
risk factor for a higher rate of adverse cardiac events. In this
sense, an increased LHR in this group could be an epiphe-
nomenon. Diastolic dysfunction with resultant abnormal ele-
vation in end-diastolic pressure and capillary wedge pressure
on exercise may have resulted in lower exercise capacity and
increased LHR on exercise despite an apparent absence of
exercise-induced ischemia. Whatever the mechanism, quanti-
tatively increased lung Tl-201 uptake in the absence of perfu-
sion abnormalities indicates a trend toward a higher cardiac
event rate.
Study limitations. The TIMI-IIIB study enrolled patients
with a strong clinical suspicion of unstable angina or non-Q
wave myocardial infarction at the time of presentation. There-
fore, the results may not be directly extrapolated to other
groups of patients, such as those with low pretest likelihood of
coronary artery disease. Furthermore, submaximal exercise for
stress perfusion imaging may contribute to a relatively high
proportion of studies with no apparent perfusion abnormalities
(40%) despite a high likelihood of coronary artery disease in
the overall patient cohort. Planar imaging used in the TIMI-
IIIB study has a somewhat lower sensitivity for the detection of
coronary artery disease than SPECT imaging, particularly in
single-vessel and for left circumflex coronary artery disease (1).
Coronary angiography at presentation was performed only in
patients randomized to the early invasive strategy. Therefore,
coronary angiographic and left ventricular ejection fraction
data are available only in 50% of patients. In keeping with
recent trends of declining mortality and infarction rates in
patients with coronary artery disease, event rates were rela-
tively low in this patient cohort. Thus, only larger differences in
the events could be detected. Finally, an increased LHR was a
predefined criterion for identification of “high risk” patients in
the presence of reversible perfusion abnormalities, thereby
leading to selection of such patients for revascularization. This
selection would certainly confound analysis of the role of an
increased LHR as a prognostic indicator. Nevertheless, despite
this factor, which could mitigate against detection of any
adverse outcome, an increased LHR continued to be associ-
ated with an adverse prognosis.
Conclusions. The results of this study indicate that in the
current era of aggressive interventional management, an in-
creased quantitative LHR on predischarge submaximal stress
Tl-201 imaging continues to be an adverse prognostic sign in
patients presenting with unstable angina or non-Q wave myo-
cardial infarction. An abnormal LHR in the absence of myo-
cardial perfusion abnormalities was seen mainly in women and
in overweight patients but nevertheless indicates a tendency
toward a higher adverse cardiac event rate.
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